vs

Side-by-side financial comparison of Idaho Strategic Resources, Inc. (IDR) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $14.6M, roughly 1.3× Idaho Strategic Resources, Inc.). Idaho Strategic Resources, Inc. runs the higher net margin — 64.3% vs -177.4%, a 241.7% gap on every dollar of revenue. On growth, Idaho Strategic Resources, Inc. posted the faster year-over-year revenue change (92.0% vs -11.5%). Idaho Strategic Resources, Inc. produced more free cash flow last quarter ($8.2M vs $-23.1M). Over the past eight quarters, Idaho Strategic Resources, Inc.'s revenue compounded faster (57.2% CAGR vs -12.2%).

Idaho Strategic Resources, Inc. is a U.S.-based natural resource company focused on the exploration, development, and production of critical and strategic minerals. Primarily operating in Idaho, it targets rare earth elements, gold, silver, and other high-demand minerals, supplying products to the clean energy, defense, and industrial manufacturing sectors across North America.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

IDR vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.3× larger
LAB
$19.6M
$14.6M
IDR
Growing faster (revenue YoY)
IDR
IDR
+103.5% gap
IDR
92.0%
-11.5%
LAB
Higher net margin
IDR
IDR
241.7% more per $
IDR
64.3%
-177.4%
LAB
More free cash flow
IDR
IDR
$31.2M more FCF
IDR
$8.2M
$-23.1M
LAB
Faster 2-yr revenue CAGR
IDR
IDR
Annualised
IDR
57.2%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
IDR
IDR
LAB
LAB
Revenue
$14.6M
$19.6M
Net Profit
$9.4M
$-34.7M
Gross Margin
68.5%
48.5%
Operating Margin
62.4%
-168.5%
Net Margin
64.3%
-177.4%
Revenue YoY
92.0%
-11.5%
Net Profit YoY
220.6%
-28.8%
EPS (diluted)
$0.62
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IDR
IDR
LAB
LAB
Q4 25
$14.6M
Q3 25
$11.1M
$19.6M
Q2 25
$9.5M
$21.8M
Q1 25
$7.3M
$40.8M
Q4 24
$7.6M
Q3 24
$6.2M
$22.1M
Q2 24
$6.1M
$22.5M
Q1 24
$5.9M
$45.5M
Net Profit
IDR
IDR
LAB
LAB
Q4 25
$9.4M
Q3 25
$3.0M
$-34.7M
Q2 25
$2.8M
$-33.5M
Q1 25
$1.6M
$-26.0M
Q4 24
$2.9M
Q3 24
$1.6M
$-26.9M
Q2 24
$2.2M
$-45.7M
Q1 24
$2.2M
$-32.2M
Gross Margin
IDR
IDR
LAB
LAB
Q4 25
68.5%
Q3 25
63.6%
48.5%
Q2 25
57.8%
48.8%
Q1 25
50.8%
48.4%
Q4 24
53.3%
Q3 24
48.7%
54.9%
Q2 24
50.2%
46.1%
Q1 24
48.1%
53.1%
Operating Margin
IDR
IDR
LAB
LAB
Q4 25
62.4%
Q3 25
23.4%
-168.5%
Q2 25
26.6%
-118.1%
Q1 25
19.3%
-80.8%
Q4 24
36.2%
Q3 24
23.4%
-120.9%
Q2 24
34.2%
-134.5%
Q1 24
36.3%
-132.2%
Net Margin
IDR
IDR
LAB
LAB
Q4 25
64.3%
Q3 25
26.8%
-177.4%
Q2 25
29.2%
-153.7%
Q1 25
22.1%
-63.8%
Q4 24
38.5%
Q3 24
25.8%
-122.0%
Q2 24
35.2%
-203.3%
Q1 24
36.8%
-70.6%
EPS (diluted)
IDR
IDR
LAB
LAB
Q4 25
$0.62
Q3 25
$0.20
$-0.09
Q2 25
$0.20
$-0.09
Q1 25
$0.12
$-0.07
Q4 24
$0.21
Q3 24
$0.12
$-0.07
Q2 24
$0.17
$-0.12
Q1 24
$0.17
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IDR
IDR
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
$2.3M
Stockholders' EquityBook value
$108.2M
$399.7M
Total Assets
$116.2M
$539.6M
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IDR
IDR
LAB
LAB
Q4 25
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q4 24
Q3 24
$210.6M
Q2 24
$6.3M
$269.8M
Q1 24
$5.3M
$287.1M
Total Debt
IDR
IDR
LAB
LAB
Q4 25
$2.3M
Q3 25
$3.0M
Q2 25
$3.3M
Q1 25
$3.7M
Q4 24
$1.7M
Q3 24
$2.9M
$55.2M
Q2 24
$2.7M
$55.1M
Q1 24
$3.3M
$55.0M
Stockholders' Equity
IDR
IDR
LAB
LAB
Q4 25
$108.2M
Q3 25
$74.3M
$399.7M
Q2 25
$49.3M
$424.5M
Q1 25
$39.8M
$454.6M
Q4 24
$37.7M
Q3 24
$33.1M
$489.3M
Q2 24
$25.4M
$510.3M
Q1 24
$21.6M
$577.3M
Total Assets
IDR
IDR
LAB
LAB
Q4 25
$116.2M
Q3 25
$83.1M
$539.6M
Q2 25
$57.7M
$557.0M
Q1 25
$48.1M
$579.6M
Q4 24
$44.0M
Q3 24
$40.8M
$681.5M
Q2 24
$32.2M
$708.7M
Q1 24
$28.7M
$777.7M
Debt / Equity
IDR
IDR
LAB
LAB
Q4 25
0.02×
Q3 25
0.04×
Q2 25
0.07×
Q1 25
0.09×
Q4 24
0.05×
Q3 24
0.09×
0.11×
Q2 24
0.11×
0.11×
Q1 24
0.15×
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IDR
IDR
LAB
LAB
Operating Cash FlowLast quarter
$10.7M
$-22.2M
Free Cash FlowOCF − Capex
$8.2M
$-23.1M
FCF MarginFCF / Revenue
56.0%
-118.1%
Capex IntensityCapex / Revenue
17.7%
4.5%
Cash ConversionOCF / Net Profit
1.15×
TTM Free Cash FlowTrailing 4 quarters
$12.4M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IDR
IDR
LAB
LAB
Q4 25
$10.7M
Q3 25
$2.4M
$-22.2M
Q2 25
$3.5M
$-20.7M
Q1 25
$2.4M
$-30.3M
Q4 24
$3.2M
Q3 24
$2.5M
$-27.9M
Q2 24
$2.6M
$-39.0M
Q1 24
$2.6M
$-62.5M
Free Cash Flow
IDR
IDR
LAB
LAB
Q4 25
$8.2M
Q3 25
$709.8K
$-23.1M
Q2 25
$2.5M
$-22.6M
Q1 25
$1.0M
$-35.3M
Q4 24
$2.1M
Q3 24
$1.9M
$-30.1M
Q2 24
$2.4M
$-41.0M
Q1 24
$2.3M
$-63.3M
FCF Margin
IDR
IDR
LAB
LAB
Q4 25
56.0%
Q3 25
6.4%
-118.1%
Q2 25
26.5%
-103.6%
Q1 25
13.8%
-86.6%
Q4 24
28.0%
Q3 24
30.4%
-136.4%
Q2 24
38.7%
-182.2%
Q1 24
38.3%
-138.9%
Capex Intensity
IDR
IDR
LAB
LAB
Q4 25
17.7%
Q3 25
15.3%
4.5%
Q2 25
10.8%
8.7%
Q1 25
19.4%
12.4%
Q4 24
13.6%
Q3 24
9.8%
10.2%
Q2 24
4.3%
8.6%
Q1 24
5.5%
1.7%
Cash Conversion
IDR
IDR
LAB
LAB
Q4 25
1.15×
Q3 25
0.81×
Q2 25
1.28×
Q1 25
1.50×
Q4 24
1.08×
Q3 24
1.56×
Q2 24
1.22×
Q1 24
1.19×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IDR
IDR

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons